Holen Sie sich die Stockscreener-App
907.68
1.24%
11.15
Handel nachbörslich:
904.58
-3.10
-0.34%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$896.53
Offen:
$891.41
24-Stunden-Volumen:
5.31M
Relative Volume:
1.18
Marktkapitalisierung:
$859.08B
Einnahmen:
$59.42B
Nettoeinkommen (Verlust:
$18.41B
KGV:
44.89
EPS:
20.2197
Netto-Cashflow:
$6.44B
1W Leistung:
+10.68%
1M Leistung:
+8.07%
6M Leistung:
+10.21%
1J Leistung:
+12.60%
1-Tages-Spanne:
$883.64
$915.22
1-Wochen-Bereich:
$809.63
$915.22
52-Wochen-Spanne:
$623.78
$935.62
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Vergleichen Sie LLY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
907.68 | 802.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
186.86 | 448.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
216.04 | 374.44B | 59.64B | 2.37B | 18.24B | 1.331 |
|
NVS
Novartis Ag Adr
|
125.01 | 237.66B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
83.86 | 206.04B | 63.99B | 19.05B | 14.72B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Bestätigt | BMO Capital Markets | Outperform |
| 2025-10-14 | Hochstufung | Erste Group | Hold → Buy |
| 2025-09-17 | Herabstufung | Berenberg | Buy → Hold |
| 2025-08-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Herabstufung | Erste Group | Buy → Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-09-13 | Fortgesetzt | Citigroup | Buy |
| 2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
| 2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-20 | Fortgesetzt | UBS | Buy |
| 2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-26 | Bestätigt | Citigroup | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | UBS | Buy |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-09-22 | Hochstufung | UBS | Neutral → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-16 | Bestätigt | BofA Securities | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-21 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
| 2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-01-23 | Eingeleitet | UBS | Buy |
| 2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-10-01 | Bestätigt | SunTrust | Buy |
| 2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Lilly, Novo Nordisk in pricing, coverage talks with Trump administration on obesity meds: Endpoints - Fierce Pharma
Wall Street gets another reason to like Eli Lilly stock, and DuPont's spin is going to plan - CNBC
Trump administration nears deals for cheaper weight-loss drugs with Novo Nordisk, Eli Lilly - statnews.com
Eli Lilly, Novo Nordisk close to White House deal on obesity drug prices - ABC News
Eli Lilly, Novo Nordisk Stocks Rise on Reported $149 Obesity Drug Deal with White House - Benzinga
Eli Lilly (LLY) in Talks for Affordable Weight Loss Drug Pricing - GuruFocus
Eli Lilly, Novo reportedly nearing U.S. deals for obesity drug prices (update) - Seeking Alpha
Trump administration is negotiating deals with Eli Lilly and Novo Nordisk to offer weight-loss drugs at reduced prices via TrumprxWSJ - MarketScreener
Lilly, Novo near White House deals to cut obesity drug prices, gain Medicare access, Endpoints News reports - Reuters
Eli Lilly (LLY) Nears Agreement on Obesity Drug Pricing with U.S. Government - GuruFocus
Eli Lilly (LLY) and Novo Nordisk (NVO) to Announce Drug Pricing Deals - GuruFocus
Eli Lilly and Novo Nordisk to strike obesity drug pricing deal with White House - Investing.com
Eli Lilly (LLY) Nears Drug Pricing Agreement with White House - GuruFocus
Lilly, Novo near White House deals to cut obesity drug prices, gain Medicare access, media reports - TradingView
Lilly and Novo Rise on Report of Deal for Medicare Coverage - Bloomberg.com
Lilly to build a new $3 billion facility in Netherlands - The Pharma Letter
Eli Lilly To Build $3B Netherlands Manufacturing Facility - InkFreeNews.com
Eli Lilly invests $3bn in Dutch manufacturing facility - Global Construction Review
Is Eli Lilly a Millionaire Maker? - AOL.com
Lilly announces plan for new $3bn facility to boost manufacturing in Europe - PMLiVE
Lilly boosts oral GLP-1 manufacturing capability with new Netherlands facility - European Pharmaceutical Review
Here’s What Weighed on Eli Lilly and Company’s (LLY) Performance - Insider Monkey
Eli Lilly to build $3B pharmaceutical plant in the Netherlands - MarketScreener
Eli Lilly (LLY) Urges Europe to Eliminate Clawback Taxes - GuruFocus
Fund Update: 18,751 ELI LILLY (LLY) shares added to WELCH & FORBES LLC portfolio - Quiver Quantitative
HSBC Ups Eli Lilly Price Target, EPS Forecasts on 'Solid' Execution, Product Portfolio - 富途牛牛
Eli Lilly to invest $3bn in new Dutch manufacturing facility - Pharmaceutical Technology
Gene Editing Market Size to Surpass USD 42.13 Billion by 2034 - GlobeNewswire Inc.
Eli Lilly to invest $3B in Dutch manufacturing hub - Silicon Canals
US pharma giant Eli Lilly to build factory in the Netherlands - medwatch.com
Are Wall Street Analysts Predicting Eli Lilly Stock Will Climb or Sink? - Barchart.com
Eli Lilly plans to build new USD 3 billion facility in Netherlands - Medical Dialogues
Eli Lilly calls on Europe to ditch clawback taxes on drugmakers - Financial Times
Pharmaceutical Giant Eli Lilly Soars on Blockbuster Drug Performance - AD HOC NEWS
Major Shareholder Cashes Out Big on Eli Lilly Stock! - TipRanks
Eli Lilly and Company (NYSE:LLY) Trading 3.9% Higher on Analyst Upgrade - MarketBeat
Lilly Endowment sells $260m in Eli Lilly shares - Investing.com
Next phase of Eli Lilly's plans in Kenosha County take shape - The Business Journals
Eli Lilly announces Q3 results, $3 billion new site, plans for oral GLP-1 approval - drugdiscoverytrends.com
Eli Lilly (LLY) to Build $3 Billion European Plant to Manufacture Weight-Loss Pill - TipRanks
Eli Lilly eyeing Philadelphia for Gateway Labs site, sources say - The Business Journals
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $930 - 富途牛牛
Tech rules Monday's stock market — plus, Eli Lilly's big comeback and new vote of confidence - CNBC
AstraZeneca, Merck, Eli Lilly to invest $120M in Virginia pharma manufacturing training center - The Business Journals
What's Up With The Rise In Eli Lilly Stock Today? - Benzinga
Eli Lilly to invest €2.7 billion in new factory near Leiden - DutchNews.nl
Lilly earmarks $3B for new European obesity pill factory - Endpoints News
Lilly Announces $1.2B Puerto Rico Expansion, Adding 100 Jobs - InkFreeNews.com
Eli Lilly to Invest $3 Billion in Netherlands Manufacturing Facility for Expanding Medicine Access - geneonline.com
Lilly to build $3 billion Dutch plant to boost weight-loss pill production - Reuters
Eli Lilly’s New Study on Brenipatide: A Potential Game-Changer in Smoking Cessation - TipRanks
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.32%
1.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):